Valmont, a provider of engineered products and infrastructure services for agriculture, reported Q2 revenues of $1.12 billion, up 6.5% year-on-year and exceeding analyst expectations by 2.6%. The company beat earnings per share estimates and slightly topped full-year revenue guidance. Despite strong results, Valmont's stock declined 3.6% following the announcement, suggesting investor expectations may have been higher than published analyst projections. The stock currently trades at $506.79. Across the building materials sector, the nine tracked stocks collectively reported revenues that beat consensus estimates by 4.5%. However, share prices have declined an average of 2.5% since earnings were released. Carlisle Companies delivered the strongest Q2 performance amongst peers, reporting revenues of $1.57 billion, up 8.3% year-on-year and outperforming expectations by 6.3%.

Valmont brings genetic testing into its personalized skincare strategy. * Written by Emily Chen * Aug 10, 2026 The Swiss skincare company is combining genetic analysis, lifestyle assessment and beauty treatments in a $1,500 program that reflects the expanding market for personalized longevity. Valmont is moving deeper into the growing longevity market with The Art of Longevity, a personalized program combining genetic testing, lifestyle assessment and skincare expertise. Developed with longevity specialist Dr. Filippo Ongaro, the initiative produces an individualized plan covering skin, sleep, mobility, nutrition and mental resilience, extending the company's traditional beauty focus into a broader interpretation of wellness. The program begins with an assessment of 146 variations across 90 genes alongside a 40-question lifestyle questionnaire. According to Valmont, the analysis considers factors including cell regeneration, oxidative stress and inflammation before informing a personalized blueprint of treatments and lifestyle priorities. Participants may then receive skincare recommendations, facials and other treatments incorporating techniques such as lymphatic drainage, fasciatherapy, Kobido and mind-body massage. The approach reflects a wider shift in the beauty and wellness industries, where personalization is increasingly moving beyond product recommendations toward biological data and lifestyle information. Valmont cites Research and Markets projections that the global longevity economy will surpass $740 billion in 2026, a market being shaped by growing interest in areas including genomics, artificial intelligence and regenerative medicine. The company's program illustrates how skincare brands are positioning themselves within that broader conversation about aging and long-term well-being. Genetic testing also introduces questions about privacy that do not arise with conventional beauty consultations. Valmont says testing is performed by certified European laboratory BMR Genomics, with participant information encrypted and anonymized in accordance with GDPR requirements. The company also states that raw genetic data remains confidential and is restricted to the individual evaluation, making data handling an important component of a service built around highly personal biological information. The Signature Longevity Blueprint costs $1,500, while personalized Mind & Body treatments begin at $295. It is currently available at La Maison Valmont locations in Madrid, Munich and New York at The Carlyle Hotel, with Beverly Hills expected to follow in 2027. Whether consumers embrace this combination of skincare and genetic analysis remains to be seen, but its arrival demonstrates how the language and tools of longevity are increasingly entering the premium beauty market.